Orphalan S.a.

Smithkline Beecham Corporation

Glaxosmithkline LLC

King's College London

Glaxo Group Limited

Actimed Therapeutics Limited

Nerre Therapeutics Limited

Faraday Pharmaceuticals, Inc.

Ronnie Maxwell Lawrence

Timothy James Morley

Naseem Amin

Alan D Borthwick

Edwin Aret

Jane Theresa Brown

Jonathan Patrick Thomas Corcoran

Bobby Neal Glover

Maria Beatriz De Castro Vasconcelos Goncalves

Maria Fumiko Tymoschenko

Matthew Jude Sharp

Sarkis Barrett Kalindjian

Jason William Beames Cooke

Sarkis Barret Kalindjian

Jonathan James Loughrey

Alan Millar

Jaclyn Raeburn

Saurabh Chitre

Natalie Louise Kelk

Andrew Simon Craig

Kiara Marissa Lobato

Andrew Justin Stewart Coats

Salima Zarah Ismail

Elaine Morten

Robin Chandra Bhattacherjee

Clare Louise Anderton

David Clapham

Melissa Joseph

Jonathan Patrick Corcoran

Alan David Borthwick

Craig Callahan

The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use

The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S-pindolol; and (ii) an organic acid, wherein the organic acid has: a pKal of greater than or equal to 2.5; and a chemical formula of CHy(CO2H), where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful in treating conditions such as cachexia, sarcopenia, a neuromuscular disorder and muscle weakness.

Organic acid addition salts of S-pindolol

The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (referred to herein as 'BHBA-001'), which, inter alia, is a (selective) retinoic acid receptor beta (RAR&#x3b2;) (e.g., RAR&#x3b2;2) agonist. The present invention also pertains to pharmaceutical compositions comprising such crystalline forms, and the use of such crystalline forms and compositions, both in vitro and in vivo, to (selectively) activate RAR&#x3b2; (e.g., RAR&#x3b2;2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR&#x3b2; (e.g., RAR&#x3b2;2), that are ameliorated by the activation of RAR&#x3b2; (e.g., RAR&#x3b2;2), etc., including, e.g., neurological injuries such as spinal cord injuries.

Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation

The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3&#xb1;0.1&#xb0;2&#x3b8; and Raman shifts 943, 1173, 1527 and 1612&#xb1;5 cm. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (referred to herein as 'BHBA-001'), which, inter alia, is a (selective) retinoic acid receptor beta (RAR&#x3b2;) (e.g., RAR&#x3b2;2) agonist. The present invention also pertains to pharmaceutical compositions comprising such crystalline forms, and the use of such crystalline forms and compositions, both in vitro and in vivo, to (selectively) activate RAR&#x3b2; (e.g., RAR&#x3b2;2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR&#x3b2;(e.g., RAR&#x3b2;2), that are ameliorated by the activation of RAR&#x3b2; (e.g., RAR&#x3b2;2), etc., including, e.g., neurological injuries such as spinal cord injuries. 

Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-l,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

[object Object]

The invention relates to 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form or a solvate thereof, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

Crystalline forms of a pyridine derivative

An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at atypical beta-adrenoceptors (also known as beta-3-adrenoceptors).

Process of preparing arylethanoldiamines

The present invention relates to a process for preparing a chloropurine compound of formula (I) 

Process for the preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol

An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at a typical beta-adrenoceptors (also known as beta-3-adrenoceptors).

Process

Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties

Growing community of inventors

Stevenage, United Kingdom

Ronnie Maxwell Lawrence